Piscataway, NJ, June 17, 2022–Camber Pharmaceuticals is pleased to announce the addition of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets to their current portfolio.
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 37 lbs.
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets from Camber are available in a 200 mg/300 mg strength, in 30 count bottles.
To find out more about Emtricitabine and Tenofovir Disoproxil Fumarate Tablets please visit https://www.camberpharma.com
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.